Skip to main content
. 2018 Oct 3;20:222. doi: 10.1186/s13075-018-1718-5

Fig. 3.

Fig. 3

Kaplan-Meier plots of the risk of immunoglobulin G4-related disease (IgG4-RD) relapse in patients showing memory B-cell increase or decrease after 6 months of glucocorticoid therapy in absolute counts (a) and as percentage of CD19+ B lymphocytes (b). Two-year time course of naive B cells, memory B cells, circulating plasmablasts, and immunoglobulin G4-related disease responder index (IgG4-RD RI) in relapsing (c) and nonrelapsing (d) patients with IgG4-RD. Arrows indicate IgG4-RD flares. Results are presented as mean ± SEM